PeptidePedia The community reference

Shenzhen Hybio Pharmaceutical (revision 7)

Old revision·19:59, 7 Sep 2025·ChainCustodyChad

This is an old revision of this page, as it stood at 19:59, 7 Sep 2025, saved by ChainCustodyChad with the summary state which lines are held in regional stock. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Shenzhen Hybio Pharmaceutical Co., Ltd.
Legal nameShenzhen Hybio Pharmaceutical Co., Ltd.
Trading nameHYB
Other designationsHybio, Hybio Pharmaceutical, 深圳翰宇药业股份有限公司
Identity
Founded2003
HeadquartersShenzhen, Guangdong, China
IndustryResearch-compound supply
Official siteVisit HYB at hybiopharmaceutical.com
Organisation infobox · conventions

Shenzhen Hybio Pharmaceutical Co., Ltd. (trading as HYB; hybiopharmaceutical.com) is a peptide active-ingredient manufacturer and contract development organisation trading as HYB from Shenzhen, Guangdong, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.[1][2]

The organisation is one of twenty-two covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]

Corporate identity and history

[edit]

Incorporated in Shenzhen in 2003, the organisation sits with the earlier incorporation dates among the entities covered on this wiki and predates the current research-peptide market by roughly a decade.[1] Shenzhen is inside the Pearl River Delta manufacturing belt, and the organisation's own material describes a business built on peptide active pharmaceutical ingredient supply and contract development rather than on catalogue distribution alone.[2]

The organisation describes itself as operating as a contract development and manufacturing organisation alongside its own listings. That is a self-published characterisation and is recorded here as one: nothing available to this wiki establishes the manufacturing arrangements behind it, and a registered business scope is a licensing fact rather than a capability finding.[2][1]

The documentary base is the registry record, the organisation's own material and purchaser-submitted test reports. No independent coverage has been identified, which is a characteristic of the sector rather than of this entity.

Distribution and dispatch

[edit]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

References

  1. ^ a b c National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
  2. ^ a b c Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
  3. ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
  4. ^ PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.